COSMICAH 2005: workshop on verification of COncurrent Systems with dynaMIC Allocated Heaps (a Satellite event of ICALP 2005) - Informal Proceedings

Lisboa Portugal, 10 July 200

RacerD: compositional static race detection

Automatic static detection of data races is one of the most basic problems in reasoning about concurrency. We present RacerD—a static program analysis for detecting data races in Java programs which is fast, can scale to large code, and has proven effective in an industrial software engineering scenario. To our knowledge, RacerD is the first inter-procedural, compositional data race detector which has been empirically shown to have non-trivial precision and impact. Due to its compositionality, it can analyze code changes quickly, and this allows it to perform continuous reasoning about a large, rapidly changing codebase as part of deployment within a continuous integration ecosystem. In contrast to previous static race detectors, its design favors reporting high-confidence bugs over ensuring their absence. RacerD has been in deployment for over a year at Facebook, where it has flagged over 2500 issues that have been fixed by developers before reaching production. It has been important in enabling the development of new code as well as fixing old code: it helped support the conversion of part of the main Facebook Android app from a single-threaded to a multi-threaded architecture. In this paper we describe RacerD’s design, implementation, deployment and impact

Classical BI: Its Semantics and Proof Theory

We present Classical BI (CBI), a new addition to the family of bunched logics which originates in O'Hearn and Pym's logic of bunched implications BI. CBI differs from existing bunched logics in that its multiplicative connectives behave classically rather than intuitionistically (including in particular a multiplicative version of classical negation). At the semantic level, CBI-formulas have the normal bunched logic reading as declarative statements about resources, but its resource models necessarily feature more structure than those for other bunched logics; principally, they satisfy the requirement that every resource has a unique dual. At the proof-theoretic level, a very natural formalism for CBI is provided by a display calculus \`a la Belnap, which can be seen as a generalisation of the bunched sequent calculus for BI. In this paper we formulate the aforementioned model theory and proof theory for CBI, and prove some fundamental results about the logic, most notably completeness of the proof theory with respect to the semantics.Comment: 42 pages, 8 figure

Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America

Background: The T-20 vs. Optimized Regimen Only Study 1 (TORO 1) was a randomized, open-label, phase 3 study of enfuvirtide (T-20), a human immunodeficiency virus type 1 (HIV-1) fusion inhibitor. Methods: Patients from 48 sites in the United States, Canada, Mexico, and Brazil with at least six months of previous treatment with agents in three classes of antiretroviral drugs, resistance to drugs in these classes, or both, and with at least 5000 copies of HIV-1 RNA per milliliter of plasma were randomly assigned in a 2:1 ratio to receive enfuvirtide plus an optimized background regimen of three to five antiretroviral drugs or such a regimen alone (control group). The primary efficacy end point was the change in the plasma HIV-1 RNA level from base line to week 24. Results: A total of 501 patients underwent randomization, and 491 received at least one dose of study drug and had at least one measurement of plasma HIV-1 RNA after treatment began. The two groups were balanced in terms of the median base-line HIV-1 RNA level (5.2 log10 copies per milliliter in both groups), median CD4+ cell count (75.5 cells per cubic millimeter in the enfuvirtide group, and 87.0 cells per cubic millimeter in the control group), demographic characteristics, and previous antiretroviral therapy. At 24 weeks, the least-squares mean change from base line in the viral load (intention- to-treat, last observation carried forward) was a decrease of 1.696 log10 copies per milliliter in the enfuvirtide group, and a decrease of 0.764 log10 copies per milliliter in the control group (P<0.001). The mean increases in CD4+ cell count were 76 cells per cubic millimeter and 32 cells per cubic millimeter, respectively (P<0.001). Reactions at the site of the injections were reported by 98 percent of patients receiving enfuvirtide. There were more cases of pneumonia in the enfuvirtide group than in the control group. Conclusions: The addition of enfuvirtide to an optimized antiretroviral regimen provided significant antiretroviral and immunologic benefit through 24 weeks in patients who had previously received multiple antiretroviral drugs and had multidrug-resistant HIV-1 infection

MORB generation beneath the ultraslow spreading Southwest Indian Ridge (9–25°E) : major element chemistry and the importance of process versus source

Author Posting. © American Geophysical Union, 2008. This article is posted here by permission of American Geophysical Union for personal use, not for redistribution. The definitive version was published in Geochemistry Geophysics Geosystems 9 (2008): Q05004, doi:10.1029/2008GC001959.We report highly variable mid-ocean ridge basalt (MORB) major element and water concentrations from a single 1050-km first-order spreading segment on the ultraslow spreading Southwest Indian Ridge, consisting of two supersegments with strikingly different spreading geometry and ridge morphology. To the east, the 630 km long orthogonal supersegment (<10° obliquity) dominantly erupts normal MORB with progressive K/Ti enrichment from east to west. To the west is the 400 km long oblique supersegment (up to 56° obliquity) with two robust volcanic centers erupting enriched MORB and three intervening amagmatic accretionary segments erupting both N-MORB and E-MORB. The systematic nature of the orthogonal supersegments' ridge morphology and MORB composition ends at 16°E, where ridge physiography, lithologic abundance, crustal structure, and basalt chemistry all change dramatically. We attribute this discontinuity and the contrasting characteristics of the supersegments to localized differences in the upper mantle thermal structure brought on by variable spreading geometry. The influence of these differences on the erupted composition of MORB appears to be more significant at ultraslow spreading rates where the overall degree of melting is lower. In contrast to the moderate and rather constant degrees of partial melting along the orthogonal supersegment, suppression of mantle melting on the oblique supersegment due to thickened lithosphere means that the bulk source is not uniformly sampled, as is the former. On the oblique supersegment, more abundant mafic lithologies melt deeper thereby dominating the more enriched aggregate melt composition. While much of the local major element heterogeneity can be explained by polybaric fractional crystallization with variable H2O contents, elevated K2O and K/Ti cannot. On the basis of the chemical and tectonic relationship of these enriched and depleted basalts, their occurrence requires a multilithology mantle source. The diversity and distribution of MORB compositions, especially here at ultraslow spreading rates, is controlled not only by the heterogeneity of the underlying mantle, but also more directly by the local thermal structure of the lithosphere (i.e., spreading geometry) and its influence on melting processes. Thus at ultraslow spreading rates, process rather than source may be the principle determiner of MORB composition.This work was originally funded in large part by NSF grants OCE-9907630 and OCE-0526905 and more recently by OPP-0425785

Consortium neuroscience of attention deficit/hyperactivity disorder and autism spectrum disorder:The ENIGMA adventure

International audienc

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

Ristola M. on työryhmien DAD Study Grp ; Royal Free Hosp Clin Cohort ; INSIGHT Study Grp ; SMART Study Grp ; ESPRIT Study Grp jäsen.Background Chronic kidney disease (CKD) is a major health issue for HIV-positive individuals, associated with increased morbidity and mortality. Development and implementation of a risk score model for CKD would allow comparison of the risks and benefits of adding potentially nephrotoxic antiretrovirals to a treatment regimen and would identify those at greatest risk of CKD. The aims of this study were to develop a simple, externally validated, and widely applicable long-term risk score model for CKD in HIV-positive individuals that can guide decision making in clinical practice. Methods and Findings A total of 17,954 HIV-positive individuals from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study with >= 3 estimated glomerular filtration rate (eGFR) values after 1 January 2004 were included. Baseline was defined as the first eGFR > 60 ml/min/1.73 m2 after 1 January 2004; individuals with exposure to tenofovir, atazanavir, atazanavir/ritonavir, lopinavir/ritonavir, other boosted protease inhibitors before baseline were excluded. CKD was defined as confirmed (>3 mo apart) eGFR In the D:A:D study, 641 individuals developed CKD during 103,185 person-years of follow-up (PYFU; incidence 6.2/1,000 PYFU, 95% CI 5.7-6.7; median follow-up 6.1 y, range 0.3-9.1 y). Older age, intravenous drug use, hepatitis C coinfection, lower baseline eGFR, female gender, lower CD4 count nadir, hypertension, diabetes, and cardiovascular disease (CVD) predicted CKD. The adjusted incidence rate ratios of these nine categorical variables were scaled and summed to create the risk score. The median risk score at baseline was -2 (interquartile range -4 to 2). There was a 1: 393 chance of developing CKD in the next 5 y in the low risk group (risk score = 5, 505 events), respectively. Number needed to harm (NNTH) at 5 y when starting unboosted atazanavir or lopinavir/ritonavir among those with a low risk score was 1,702 (95% CI 1,166-3,367); NNTH was 202 (95% CI 159-278) and 21 (95% CI 19-23), respectively, for those with a medium and high risk score. NNTH was 739 (95% CI 506-1462), 88 (95% CI 69-121), and 9 (95% CI 8-10) for those with a low, medium, and high risk score, respectively, starting tenofovir, atazanavir/ritonavir, or another boosted protease inhibitor. The Royal Free Hospital Clinic Cohort included 2,548 individuals, of whom 94 individuals developed CKD (3.7%) during 18,376 PYFU (median follow-up 7.4 y, range 0.3-12.7 y). Of 2,013 individuals included from the SMART/ESPRIT control arms, 32 individuals developed CKD (1.6%) during 8,452 PYFU (median follow-up 4.1 y, range 0.6-8.1 y). External validation showed that the risk score predicted well in these cohorts. Limitations of this study included limited data on race and no information on proteinuria. Conclusions Both traditional and HIV-related risk factors were predictive of CKD. These factors were used to develop a risk score for CKD in HIV infection, externally validated, that has direct clinical relevance for patients and clinicians to weigh the benefits of certain antiretrovirals against the risk of CKD and to identify those at greatest risk of CKD.Peer reviewe